Pasithea Therapeutics (KTTA) Long-Term Debt Repayments (2023 - 2025)
Pasithea Therapeutics recorded quarterly Long-Term Debt Repayments of $179310.0 in Q1 2025, up 34.48% quarter-over-quarter from $133335.0 in Q3 2023.
Pasithea Therapeutics' Long-Term Debt Repayments history runs 2 years deep, the most recent figure standing at $179310.0 for Q1 2025.
- In Q1 2025, Long-Term Debt Repayments changed N/A year-over-year to $179310.0; the TTM figure through Mar 2025 stood at $443413.0 (changed N/A YoY), while the FY2023 annual figure was $392354.0, changed N/A from the prior year.
- Long-Term Debt Repayments came in at $179310.0 for Q1 2025 at Pasithea Therapeutics, up from $133335.0 in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $179310.0 in Q1 2025 to a low of $128251.0 in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 179,310.00 |
| Mar 31, 2025 | 179,310.00 |
| Sep 30, 2023 | 133,335.00 |
| Sep 30, 2023 | 133,335.00 |
| Jun 30, 2023 | 130,768.00 |
| Jun 30, 2023 | 130,768.00 |
| Mar 31, 2023 | 128,251.00 |
| Mar 31, 2023 | 128,251.00 |